Cardiovascular Drugs and Therapy
Overview
Cardiovascular Drugs and Therapy is a peer-reviewed journal that focuses on the latest advancements in the field of cardiovascular pharmacotherapy. It provides a platform for researchers, clinicians, and pharmacologists to share their findings and insights on the development, efficacy, and safety of drugs used in the treatment of cardiovascular diseases. The journal covers a wide range of topics, including drug discovery, clinical trials, pharmacokinetics, and therapeutic strategies, making it an essential resource for professionals involved in cardiovascular medicine.
Details
Details
Abbr.
Cardiovasc Drugs Ther
Start
1987
End
Continuing
Frequency
Six no. a year
p-ISSN
0920-3206
e-ISSN
1573-7241
Country
United States
Language
English
Specialties
Pharmacology
Cardiology & Vascular Diseases
Cardiology & Vascular Diseases
Metrics
Metrics
h-index / Ranks: 4440
79
SJR / Ranks: 3979
973
CiteScore / Ranks: 2894
7.00
JIF / Ranks: 2884
3.4
Recent Articles
1.
Pedrosa M, da Silva A, Trevisani V
Cardiovasc Drugs Ther
. 2025 Mar;
PMID: 40088397
No abstract available.
2.
Wang J, Wehrens X, Grande-Allen K
Cardiovasc Drugs Ther
. 2025 Mar;
PMID: 40056325
No abstract available.
3.
Sun Y, Xiao L, Chen L, Wang X
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 40009315
Background: The therapeutic prowess of doxorubicin in oncology is marred by its cardiotoxic consequences, manifesting as cardiac remodeling. Pathophysiological alterations triggered by doxorubicin include inflammatory cascades, fibrotic tissue deposition, vascular...
4.
Ba L, Wu N, Feng X, Wang R, Zhao Z, Wang R, et al.
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39976876
Purpose: The purpose of this study was to investigate the protective effects of biochanin A (BCA) on cardiac hypertrophy and to elucidate the underlying molecular mechanisms. The research question was...
5.
Xu J, Zheng Q, Cui Y, Wang J, Xie Y, Li L, et al.
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39964602
Purpose: Transcatheter aortic valve replacement (TAVR) has emerged as a critical innovation for managing severe aortic stenosis, prompting the development of numerous clinical practice guidelines worldwide. This study systematically evaluates...
6.
Hu Y, Wang S, Zhang C, He F, Jiang Y, Chen R, et al.
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39954170
Purpose: The use of doxorubicin (DOX), a potent chemotherapy drug, is limited by its detrimental effects on the heart. This cardiotoxicity is primarily driven by oxidative stress and inflammation. TRIM35...
7.
Fordham M, Lyubarova R, Sidhu M
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39951206
No abstract available.
8.
Muric M, Srejovic I, Novakovic J, Zivkovic V, Jovic J, Sretenovic J, et al.
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39913081
Purpose: The idea behind this study was to assess the effects of empagliflozin and sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF) and underlying molecular mechanisms. Methods: HF was...
9.
10.
Zhang J, Yan T, Liu R, Li Y, Zhou M, Wang H, et al.
Cardiovasc Drugs Ther
. 2025 Feb;
PMID: 39907871
Purpose: Spironolactone has been reported to increase the risk of upper gastrointestinal bleeding in patients. We aimed to validate this perspective in a population of patients undergoing percutaneous coronary intervention...